NASDAQ · NAII

Natural Alternatives International Inc.

$2.40 +$0.08 (+3.45%) 1D Market open

Key Metrics

$14.56M
Market cap
P/E · TTM
Revenue · TTM
−$14.37M
Net income
EPS · TTM $-2.39
Dividend yield
Free cash flow −$9.02M
Beta · 1Y 0.82
EBITDA · TTM −$7.24M
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 20
    From its Jan 30 high, the share price fell 48%.

    Peak close $4.10 on Jan 30; trough close $2.15 on Jul 20. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -48%
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Feb 17
    The stock moved -26.8% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 17
  • Feb 5
    The stock moved -15.7% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 5

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$14.56M
Enterprise value
Shares outstanding6.3M
52-wk range$2.09 – $4.96
Avg volume · 20D15.3K
Net cash
Book value / share$10.50
IndustryMedicinal Chemicals & Botanical Products
ExchangeNASDAQ
About Natural Alternatives International Inc.
IPO dateSep 1, 1987
Employees234

Natural Alternatives International Inc is engaged in formulating, manufacturing, and marketing nutritional supplements. It offers vitamins, minerals, herbs, and other supplements, as well as other healthcare products, to customers within the United States and internationally.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating
Net
FCF
ROE / ROIC -19.7% · -26.7%

Financial Health

Current ratio1.64
Quick ratio0.87
Debt / equity
Debt / EBITDA
Net cash
Working capital$24.87M

Cash Flow · TTM

Operating CF −$4.51M
Capex −$4.52M
Free cash flow −$9.02M
Buybacks $89.00K
Dividends paid
Shareholder yield 0.6%

Piotroski F-Score

2 / 9
Weak fundamentals · 2 of 9 signals passing

Altman Z-Score

Insufficient balance-sheet inputs

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings